MISSISSAUGA, ON, April 29 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX:NRI.to - News), a drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2010.
